News
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
KURMA PARTNERS, MEMBRE DU GROUPE EURAZEO ET ACTIONNAIRE-FONDATEUR D’IMCHECK, ANNONCE LA CESSION DE LA BIOTECH A IPSEN POUR UN MONTANT POUVANT ATTEINDRE 1 MILLIARD D’EUROS
KURMA PARTNERS cède ImCheck Therapeutics à IPSEN pour 1 milliard d’euros après succès dans la création et développement d'anticorps d'immunothérapie -
COMMUNIQUÉ RÉGLEMENTÉ
KURMA PARTNERS, A MEMBER OF THE EURAZEO GROUP AND FOUNDING INVESTOR OF IMCHECK THERAPEUTICS, ANNOUNCES THE SALE OF THE BIOTECH COMPANY TO IPSEN FOR UP TO €1 BILLION
Kurma Partners, a member of the Eurazeo group, announces the sale of ImCheck Therapeutics to Ipsen for up to €1 billion. The biotech company focuses on immunotherapy for cancer treatment, confirming Kurma's success in creating and supporting biotech ventures -
-
COMMUNIQUÉ DE PRESSE
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Ipsen reports strong sales growth in first nine months of 2025, upgrades full-year guidance, and announces acquisition of ImCheck Therapeutics. Financial results and pipeline updates detailed -
-
-
-